Do neurologists in Germany adhere to the national Parkinson’s disease guideline?

Sabrina Schröder1 Institute of Clinical Pharmacology, Charité University Medicine, CCM, Berlin, GermanyCorrespondence[email protected]

Daniel Kuessner2 Basilea Pharmaceutica, Basel, Switzerland

Guy Arnold3 Department of Neurology, Sindelfingen-Böblingen Hospital, Sindelfingen, Germany

York Zöllner4 Mapi Values, Houten, The Netherlands

Eddie Jones5 Adelphi Group Products, Macclesfield, UK

Marion Schaefer1 Institute of Clinical Pharmacology, Charité University Medicine, CCM, Berlin, Germany

Pages 103-110 | Published online: 07 Mar 2011

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

RascolOGoetzCKollerWPoeweWSampaioCTreatment interventions for Parkinson’s disease: an evidence based assessmentLancet20023591589159812047983
PubMed Web of Science ®Google Scholar
WojteckiLSüdmeyerMSchnitzlerAThe current treatment of Parkinson’s diseaseDtsch Arztebl2007104A25132522
Google Scholar
DamianoAMMcGrathMMWillianMKEvaluation of a measurement strategy for Parkinson’s disease: assessing patient health-related quality of lifeQual Life Res200098710010981209
PubMed Web of Science ®Google Scholar
DodelRCSingerMSKöhne-VollandRThe economic impact of Parkinson’s disease. An estimation based on a 3-month prospective analysisPharmacoeconomics19981429931210186468
PubMed Web of Science ®Google Scholar
DodelRCBergerKOertelWHHealth-related quality-of-life and health-care utilisation in patients with Parkinson’s disease: impact of motor fluctuations and dyskinesiasPharmacoeconomics2001191013103811735671
PubMed Web of Science ®Google Scholar
DowdingCHShentonCLSalekSSA review of the health-related quality of life and economic impact of Parkinson’s diseaseDrugs Aging20062369372117020395
PubMed Web of Science ®Google Scholar
EggertKDeuschlGGasserTLeitlinie Parkinson-Syndrome, 2 AusgStuttgartThieme2005
Google Scholar
Klinische “Leitlinien” der deutschen Gesellschaft für NeurologieLeitlinie für Diagnostik und Therapie in der NeurologieStuttgart, GermanyThieme2003
Google Scholar
OertelWHQuinnNParkinsonismBrandtTDienerHCCaplanLRNeurological Disorders: Course and TreatmentSan DiegoAcademic Press200210211079
Google Scholar
OlanowCWWattsRLKollerWCAn algorithm (decision tree) for the management of Parkinson’s disease: treatment guidelinesMov Disord200156S1S88
Google Scholar
Parkinson’s Disease Consensus Working Group (PDCWG)Guidelines for the management of Parkinson’s diseaseHosp Med1998594694809775275
PubMed Web of Science ®Google Scholar
GKV-Modernisierungsgesetz Bundesgesetzblatt Jahrgang 2003 Teil I No. 55, ausgegeben zu Bonn am 19. November 2003. Gesetz zur Modernisierung der gesetzlichen Krankenversicherung (GKV-Modernisierungsgesetz – GMG); vom 14. November 2003.
Google Scholar
EggertKLarischADodelRBormannCOertelWHAwareness and knowledge of the clinical practice guideline on Parkinson’s disease among German neurologistsEur Neurol20096121622219176962
PubMed Web of Science ®Google Scholar
LarischAOertelWHEggertKAttitudes and barriers to clinical practice guidelines in general and to the guideline on Parkinson’s disease. A National Survey of German neurologists in private practiceJ Neurol20092561681168819479167
PubMed Web of Science ®Google Scholar
AskmarkHAntonovKAquiloniusSMThe increased utilisation of dopamine agonists and the introduction of COMT inhibitors have not reduced levodopa consumption – a nation-wide perspective in SwedenParkinsonism Relat Disord2003927127612781593
PubMed Web of Science ®Google Scholar
LeoniOMartignoniECosentinoMDrug prescribing patterns in Parkinson’s disease: a pharmacoepidemiological survey in a cohort of ambulatory patientsPharmacoepidemiol Drug Saf20021114915711998540
PubMed Web of Science ®Google Scholar
AndersonPBenfordMHarrisNKaravaliMPiercyJReal-world physician and patient behaviour across countries: Disease-Specific Programmes – a means to understandCurr Med Res Opin2008243063307218826746
PubMed Web of Science ®Google Scholar
http://www.esomar.org/uploads/pdf/professional-standards/ICCESOMAR_Code_English.pdf
Google Scholar
HughesAJDanielSEKilfordLLeesAJAccuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 casesJ Neurol Neurosurg Psychiatry1992551811841564476
PubMed Web of Science ®Google Scholar
MearaJBhowmickBLHobsonPAccuracy of diagnosis in patients with presumed Parkinson’s diseaseAge Ageing1999289910210350403
PubMed Web of Science ®Google Scholar
MarsdenCDParkesJDSuccess and problems of long-term levodopa therapy in Parkinson’s diseaseLancet1977134534964868
PubMed Web of Science ®Google Scholar
AlvesGWentzel-LarsenTAarslandDLarsenJPProgression of motor impairment and disability in Parkinson disease: a population-based studyNeurology2005651436144116275832
PubMed Web of Science ®Google Scholar
MöllerJCKörnerYDodelRCPharmacotherapy of Parkinson’s disease in GermanyJ Neurol200525292693515765268
PubMed Web of Science ®Google Scholar
MüllerTVossBHellwigKJosef SteinFSchulteTPrzuntekHTreatment benefit and daily drug costs associated with treating Parkinson’s disease in a Parkinson’s disease clinicCNS Drugs2004181051114728057
PubMed Web of Science ®Google Scholar
YamamotoMPractice guidelines for Parkinson’s diseaseParkinsonism Rel Disord20039S111S115
Web of Science ®Google Scholar
Klinische “Leitlinien“ der deutschen Gesellschaft für NeurologieLeitlinie für Diagnostik und Therapie in der NeurologieStuttgartThieme2008
Google Scholar
AntoniniATolosaEMizunoYYamamotoMPoeweWHA reassessment of risks and benefits of dopamine agonists in Parkinson‘s diseaseLancet Neurol2009892993719709931
PubMed Web of Science ®Google Scholar
CabanaMDRandCSPoweNRWhy don’t physicians follow clinical practice guidelines? A framework for improvementJAMA19992821458146510535437
PubMed Web of Science ®Google Scholar
GrimshawJMRussellITEffect of clinical guidelines on medical practice: a systematic review of rigorous evaluationsLancet1993342131713227901634
PubMed Web of Science ®Google Scholar
GrimshawJMEcclesMThomasRToward evidence-based quality improvement. Evidence (and its limitations) of the effectiveness of guideline dissemination and implementation strategies 1966–1998J Gen Intern Med200621Suppl 2S14S2016637955
PubMed Web of Science ®Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Do neurologists in Germany adhere to the national Parkinson’s disease guideline?

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Do neurologists in Germany adhere to the national Parkinson’s disease guideline?

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date